Introduction
Transitional cell cancer (TCC) of the renal pelvis and ureters (upper urinary tract) are relatively rare. Tumors of the renal pelvis account for approximately 10% of all renal tumors and approximately 5% of all TCC. Ureteral tumors are even more uncommon, occurring with onequarter the frequency of renal pelvis tumors. The mean age in patients who develop upper urinary tract tumors is 65 years. The incidence of TCC increases with age. Moreover, TCC tumors are rarely found at autopsy [1] . Nephro-ureterectomy with excision of the bladder cuff is considered the standard therapy in patients with renal pelvis TCC, regionally extensive disease, and high-grade or high-stage lesions. Few therapeutic options exist for bilateral tumors or contralateral recurrent tumor after unilateral nephro-ureterectomy. Surgical removal leads to chronic hemodialysis with impaired quality of live and reduced overall survival. In an effort to avoid hemodialysis, we report on a patient with pT2 G3 TCC of the renal pelvis in a single remaining kidney singular renal unit after contralateral nephro-ureterectomy 30 years ago who was treated with single-session robotic radiosurgery. To our knowledge, this is the first report on radiosurgery for TCC of the renal pelvic system.
Case Presentation

Radiosurgery system
The CyberKnife robotic radiosurgery system (Accuray Inc., Sunnyvale, CA, USA) consists of a 6-MV compact linear accelerator (LINAC) mounted on a computer-controlled six-axis robotic manipulator. Integral to the system are orthogonally positioned x-ray cameras which acquire images during treatment. The images are processed automatically to identify radiographic features, and are registered to the treatment planning study to measure the position of the treatment site in real time. The system adapts to changes in patient position during treatment by acquiring targeting images repeatedly and adjusting the direction of the treatment beam accordingly. The treatment beam can be directed from hundreds of angles anterior and lateral to the patient.
Respiratory motion compensation
In order to compensate for renal tumor motion, it is necessary to know the internal position of the target throughout treatment. At any given time, the stereo X-ray system can acquire images to establish the tumor position. Conventionally, small gold fiducials implanted in the proximity of the target are identified in both images and used to compute the 3D target position. While this provides accurate information on the tumor location at the instant the X-rays are taken, this is not sufficient to obtain real-time motion information. In the present system, the position of the chest is measured continuously by an external camera array that tracks the position of infrared markers on the patient's chest, and the location of the tumor is detected periodically in the x-ray images. A series of internal and external position measurements taken at the same time is used to establish a correlation model. Throughout treatment, frequent measurements of both positions are used to check and update the model [2] .
The 75-year-old male patient underwent left-sided nephro-ureterectomy 30 years prior to radiosurgery treatment due to idiopathic hydronephrosis. Four years ago, he developed recurrent TCC of the renal pelvis which was treated several times by ureterorenoscopic excisions and multiple laser coagulations. Finally, a partial resection of the renal pelvis was performed for pT2 G3 TCC, as the patient refused nephro-ureterectomy and hemodialysis. One year later, recurrent disease was documented by high-resolution CT scan, ureterorenoscopic biopsy (>pT1G3), and positive cytology. Again, nephro-ureterectomy was offered but refused by the patient. In an effort to avoid hemodialysis, the patient urged us to consider any therapeutic alternative, and single-session radiosurgery was offered.
Informed consent was obtained based on no clinical experience existing at this time for these sorts of tumors. Baseline serum creatinine was 2.1 ng/ml. Two gold fiducials were implanted percutaneously into the renal parenchyma by ultrasound guidance on the right side. A third fiducial was fixed to the tip of a JJ catheter and placed at the upper renal pelvis to increase tracking accuracy of the tumor located in the renal pelvis. Treatment planning was performed based on helical 1-mm CT images done one day after fiducial implantation ( Figure  1) . The treatment volume was defined by the attending urologist taking into account the anatomical location of the tumors in the renal pelvis as the results of diagnostic ureterorenoscopy performed the day before radiosurgery (Figure 2) . In a single-session procedure, 25 Gy was delivered to the 70% isodose. Figure 3 shows the DVH of the renal parenchyma. Fifty percent of the renal parenchyma received 8 Gy or less and only 25 % of the parenchyma received 12 Gy or more, even though the treatment volume in the renal pelvis was relatively large and maximum dose was above 30 Gy. The radiosurgical procedure was completely uneventful, and the patient was followed by routine video ureterorenoscopy, cystoscopy and photodynamic diagnostic as well as CT scans every three months. On last follow-up 30 months after treatment, renal function was still unchanged (serum creatinine 2.0 ng/ml) and no recurrent tumor could be detected (Figure 4 ).
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